Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer

Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial looked to combine antiangiogenic therapy with a fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Laslett, Nicole F., Park, SuJung, Masters, Gregory A., Biggs, David D., Schneider, Charles J., Misleh, Jamal G., Suppiah, Kathir, Simpson, Pamela S., Grubbs, Stephen, Wozniak, Timothy F., Guarino, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051222/
https://www.ncbi.nlm.nih.gov/pubmed/29905018
http://dx.doi.org/10.1002/cam4.1569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051222/
https://www.ncbi.nlm.nih.gov/pubmed/29905018
http://dx.doi.org/10.1002/cam4.1569

Ejemplares similares